DOCSLIB.ORG

Mucin 16 and Kallikrein 13 As Potential Prognostic Factors in Colon Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mucin 16 and Kallikrein 13 As Potential Prognostic Factors in Colon Cancer Original Article Tumor Biology July 2019: 1–10 Ó The Author(s) 2019 Mucin 16 and kallikrein 13 as potential Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/1010428319860728 prognostic factors in colon cancer: journals.sagepub.com/home/tub Results of an oncological 92-multiplex immunoassay Kajsa Bjo¨rkman1,2 , Harri Mustonen1, Tuomas Kaprio1, Caj Haglund1,3,4* and Camilla Bo¨ckelman1,3,4* Abstract Colon cancer represents one of the most common cancers in the world. Despite improved treatment, mortality remains high. In order to improve the assessment of prognosis for colon cancer patients, identifying new prognostic markers remains necessary. We analyzed preoperative serum samples from 148 colon cancer patients surgically treated at Helsinki University Hospital from 1998 through 2002 using a multiplex proximity extension assay (Oncology II panel, Olink Bioscience, Uppsala, Sweden), a panel constituting 92 immunological and oncological markers. We performed uni- variate and multivariate analyses on these patients and calculated the disease-specific survival among patients using the log-rank test for Kaplan–Meier estimates. In the univariate survival analysis of 92 biomarkers, 26 resulted in p \ 0.1. Among these, eight biomarkers emerged as statistically significant (p \ 0.05). Patients with low levels of kallikrein 13 had a poor prognosis. Moreover, patients with high levels of amphiregulin, carcinoembryonic antigen-related adhesion mole- cule 5, interleukin 6, mucin 16, syndecan 1, transforming growth factor alpha, and vimentin also had a poor prognosis. In the multivariate analysis, kallikrein 13 and mucin 16 emerged as independent prognostic markers. The role of kallikrein 13, a member of the serine protease kallikrein biomarker family, in tumorigenesis remains unclear. Mucin 16 is also known as carbohydrate antigen 125, a well-known ovarian cancer biomarker. Patients with low levels of kallikrein 13 (hazard ratio: 0.36; 95% confidence interval: 0.14–0.92; p = 0.033) and high levels of mucin 16 (hazard ratio: 3.15; 95% confidence interval: 1.68–5.93; p \ 0.005) had a poor prognosis. Mucin 16 and kallikrein 13 represent independent prog- nostic markers for colon cancer. Furthermore, the clinical utility of mucin 16 and kallikrein 13 serum tests warrants addi- tional investigation. Keywords Colon cancer, proximity extension assay, MUC-16, KLK13, prognosis Date received: 22 December 2018; accepted: 7 June 2018 1 Introduction Research Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, Finland 2Meilahti Hospital, Helsinki, Finland Colorectal cancer (CRC), the third most common can- 3 cer with the second highest mortality rate in the world,1 Department of Surgery, University of Helsinki, Helsinki, Finland 4Helsinki University Hospital, Helsinki, Finland consists of colon cancer (CC) and rectal cancer. These divisions result from differences in their pathophysiol- *Shared last authorship. ogy and histology. In the Nordic countries, CRC has a 5-year overall survival of 65%.2 Corresponding author: Kajsa Bjo¨rkman, Meilahti Hospital, P.O. Box 340, Haartmaninkatu 4, Serum carcinoembryonic antigen (CEA) is routinely 00029 Helsinki, Finland. 3 used in patient follow-up. Other tumor markers, such Email: [email protected] Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). 2 Tumor Biology as IL-8, prolactin, and carbohydrate antigen 19-9 Table 1. Patient characteristics in 148 colon cancer patients. (CA19-9), are comparable to CEA, but fall short in terms of adding value to prognostics.4,5 However, an n (%) elevated CA19-9 level in CRC patients with lymph Gender node invasion serves as an independent prognostic Female 85 (57) marker and may carry further prognostic value along- Male 63 (43) side an elevated CEA level.5,6 Age We continue to need new and accurate blood-based Median (IQR), years 69.5 (58.2–77.6) Dukes stage biomarkers. Proximity ligation assay (PLA) and prox- A 21 (14) imity extension assay (PEA) represent homogeneous B 54 (36) immunoassays with demonstrated sensitivity and speci- C 51 (35) ficity.7,8 In PEA, upon binding to the target protein, D 22 (15) Histologic type antibodies linked to oligonucleotides are pair-bound Adenocarcinoma 132 (89) and quantified using real-time quantitative polymerase Mucinous 16 (11) chain reaction (PCR).8 A promising prognostic algo- Side rithm for CRC patients emerged in a recent study using Right 86 (58) the Proseek Multiplex Oncology I v296 3 96 immunoas- Left 62 (42) 9 say (Olink Bioscience, Uppsala, Sweden). Furthermore, IQR: interquartile range. by means of Olink technology, metabolic syndrome patients with low levels of hepatocyte growth factor and endothelial cell-specific molecule-1 carried an increased Protein profiling risk of developing CRC.10 We determined 92 oncology-associated protein biomarker Thus, in this study, we aimed to screen for biomar- levels involved in tumorigenesis using the Proseek kers that can be used to evaluate CC prognosis using Multiplex Oncology II immunoassay panel (Olink the Proseek Multiplex Oncology II panel. Bioscience; Table 2, Supplementary Table 2). The selected biomarkers mirror different biological mechanisms, such Patients and methods as angiogenesis, cell signaling, cell cycle control, and inflammation. Patient information was blinded to the Patients Olink Bioscience personnel who processed the samples The cohort constituted 148 consecutive CC patients according to their manual, checked the quality of the out- operated on at Helsinki University Hospital between put data, and normalized the measurement results. In PEA, 1 mL of the sample was incubated with 1998 and 2002. The mean age of the patients reached oligonucleotide-marked antibodies pair-bound to the 67.8 (range: 31.7–92.6), and 85 (57%) were women. fitting targets.8 In brief, pairs of oligonucleotide-labeled Comorbidities of the patients were recorded and corre- antibody probes bind to their targeted protein, and if sponded to that of their age group (Supplementary the two probes are brought in close proximity, the oli- Table 1). None of the patients received neoadjuvant gonucleotides will hybridize in a pair-wise manner. The chemotherapy. According to the Dukes stage classifica- addition of a DNA polymerase leads to a proximity- tion, 21 patients had stage A disease, 54 had stage B, 51 dependent DNA polymerization event, generating a had stage C, and 22 had stage D disease. For the sub- unique PCR target sequence. The resulting DNA group analysis, we combined stages A and B (n = 75 sequence is subsequently detected and quantified using patients) and C and D (n = 73 patients; Table 1). In a microfluidic real-time PCR instrument (Biomark total, tumor histology for 131 (89%) patients indicated HD, Fluidigm Corporation, San Fransisco, USA). non-mucinous adenocarcinoma, while for 16 (11%) patients, it indicated mucinous. Data normalization of protein profiling Serum samples The concentrations of the biomarkers were determined as the relative quantification using the normalized pro- Serum samples were drawn after one night’s fasting tein expression (NPX). Normalization was performed according to the hospital’s routine procedures, a med- by subtracting extension control Ct values and inter- ian of 1 day prior to surgery (range: 27 days) alongside plate control Ct values from the analyte Ct values. A other laboratory tests. Without delay, samples were run time specific correction factor was used to correct transported to the laboratory, centrifugated, aliquoted, for normal background level. NPX is an arbitrary unit and stored at 280°C until assayed. on a log2 scale, inverted to that of the raw Bjo¨rkman et al. 3 Table 2. List of biomarkers analyzed using the proximity extension assay with the Olink Oncology IIÓ panel. Biomarker Median (pg/mL) IQR (pg/mL) HR 95% CI p valuea 5’-NT 9.26 8.74–9.77 1.25 0.87–1.81 0.518 ABL1 3.19 2.54–3.88 1.15 0.84–1.58 0.728 ADAM 8 3.95 3.73–4.26 1.95 0.94–4.06 0.323 ADAM-TS 15 3.40 3.01–3.77 2.19 1.18–4.04 0.095 ANXA1 1.28 0.95–1.67 1.31 0.91–1.89 0.413 AREG 2.36 1.92–3.00 1.89 1.38–2.58 0.003 CAIX 2.53 2.06–3.40 0.94 0.69–1.26 0.935 CD160 4.67 4.34–5.19 1.08 0.69–1.70 0.935 CD207 2.13 1.86–2.49 1.05 0.55–2.01 0.967 CD27 7.73 7.41–8.13 1.37 0.79–2.38 0.543 CD48 6.36 6.09–6.66 1.45 0.70–3.00 0.628 CD70 3.36 3.10–3.81 1.13 0.68–1.88 0.935 CEACAM1 7.09 6.99–7.22 1.50 0.23–9.81 0.935 CEACAM5 2.50 1.82–3.63 1.32 1.13–1.54 0.011 CPE 3.16 2.93–3.52 1.14 0.53–2.46 0.935 CRNN 4.82 4.21–5.40 1.05 0.74–1.48 0.957 CTSV 2.49 2.07–2.86 0.59 0.36–0.98 0.202 CXCL13 8.06 7.58–8.66 1.32 0.96–1.81 0.343 CXL17 4.32 3.95–4.81 1.01 0.46–1.54 0.983 CYR61 4.20 3.86–4.57 1.56 0.96–2.54 0.323 DKN1A 3.83 2.91–4.68 0.98 0.78–1.22 0.967 DLL1 8.97 8.72–9.29 1.83 0.90–3.72 0.347 EGF 7.87 7.05–8.68 1.06 0.84–1.34 0.935 EPHA2 1.43 1.15–1.83 1.93 1.16–3.22 0.095 ERBB2 6.57 6.40–6.79 1.14 0.40–3.26 0.961 ERBB3 7.35 7.20–7.53 0.91 0.31–2.67 0.967 ERBB4 4.47 4.26–4.70 1.18 0.48–2.88 0.935 ESM-1 8.81 8.46–9.13 1.53 0.82–2.85 0.442 FADD 2.20 1.48–3.10 1.08 0.83–1.40 0.897 FASLG 8.27 7.93–8.57 0.92 0.50–1.71 0.957 FCRLB 1.48 1.06–2.12 1.33 0.96–1.84
Load more

Recommended publications
  • To Study Mutant P53 Gain of Function, Various Tumor-Derived P53 Mutants
    Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression. A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science By Shama K Khokhar M.Sc., Bilaspur University, 2004 B.Sc., Bhopal University, 2002 2007 1 COPYRIGHT SHAMA K KHOKHAR 2007 2 WRIGHT STATE UNIVERSITY SCHOOL OF GRADUATE STUDIES Date of Defense: 12-03-07 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION BY SHAMA KHAN KHOKHAR ENTITLED Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science Madhavi P. Kadakia, Ph.D. Thesis Director Daniel Organisciak , Ph.D. Department Chair Committee on Final Examination Madhavi P. Kadakia, Ph.D. Steven J. Berberich, Ph.D. Michael Leffak, Ph.D. Joseph F. Thomas, Jr., Ph.D. Dean, School of Graduate Studies 3 Abstract Khokhar, Shama K. M.S., Department of Biochemistry and Molecular Biology, Wright State University, 2007 Differential effect of TAp63γ mutants on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression. p63, a member of the p53 gene family, known to play a role in development, has more recently also been implicated in cancer progression. Mice lacking p63 exhibit severe developmental defects such as limb truncations, abnormal skin, and absence of hair follicles, teeth, and mammary glands. Germline missense mutations of p63 have been shown to be responsible for several human developmental syndromes including SHFM, EEC and ADULT syndromes and are associated with anomalies in the development of organs of epithelial origin.
    [Show full text]
  • Depletion of the Third Complement Component Ameliorates Age- Dependent Oxidative Stress and Positively Modulates Autophagic Activity in Aged Retinas in a Mouse Model
    Hindawi Oxidative Medicine and Cellular Longevity Volume 2017, Article ID 5306790, 17 pages https://doi.org/10.1155/2017/5306790 Research Article Depletion of the Third Complement Component Ameliorates Age- Dependent Oxidative Stress and Positively Modulates Autophagic Activity in Aged Retinas in a Mouse Model 1 1 1 1 Dorota Rogińska, Miłosz P. Kawa, Ewa Pius-Sadowska, Renata Lejkowska, 1 2 3,4 3,4 Karolina Łuczkowska, Barbara Wiszniewska, Kai Kaarniranta, Jussi J. Paterno, 5 1 2,6 Christian A. Schmidt, Bogusław Machaliński, and Anna Machalińska 1Department of General Pathology, Pomeranian Medical University, Al. Powstancow Wlkp. 72, 70-111 Szczecin, Poland 2Department of Histology and Embryology, Pomeranian Medical University, Al. Powstancow Wlkp. 72, 70-111 Szczecin, Poland 3Department of Ophthalmology, Institute of Clinical Medicine, University of Eastern Finland, 70211 Kuopio, Finland 4Department of Ophthalmology, Kuopio University Hospital, 70211 Kuopio, Finland 5Clinic for Internal Medicine C, University of Greifswald, 17475 Greifswald, Germany 6Department of Ophthalmology, Pomeranian Medical University, Al. Powstancow Wlkp. 72, 70-111 Szczecin, Poland Correspondence should be addressed to Anna Machalińska; [email protected] Received 25 April 2017; Revised 28 June 2017; Accepted 9 July 2017; Published 8 August 2017 Academic Editor: Kota V. Ramana Copyright © 2017 Dorota Rogińska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The aim of the study was to investigate the influence of complement component C3 global depletion on the biological structure and function of the aged retina. In vivo morphology (OCT), electrophysiological function (ERG), and the expression of selected oxidative stress-, apoptosis-, and autophagy-related proteins were assessed in retinas of 12-month-old C3-deficient and WT mice.
    [Show full text]
  • Kallikrein 13: a New Player in Coronaviral Infections
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.01.971499; this version posted March 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Kallikrein 13: a new player in coronaviral infections. 2 3 Aleksandra Milewska1,2, Katherine Falkowski2, Magdalena Kalinska3, Ewa Bielecka3, 4 Antonina Naskalska1, Pawel Mak4, Adam Lesner5, Marek Ochman6, Maciej Urlik6, Jan 5 Potempa2,7, Tomasz Kantyka3,8, Krzysztof Pyrc1,* 6 7 1 Virogenetics Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian 8 University, Gronostajowa 7a, 30-387 Krakow, Poland. 9 2 Microbiology Department, Faculty of Biochemistry, Biophysics and Biotechnology, 10 Jagiellonian University, Gronostajowa 7, 30-387 Krakow, Poland. 11 3 Laboratory of Proteolysis and Post-translational Modification of Proteins, Malopolska 12 Centre of Biotechnology, Jagiellonian University, Gronostajowa 7a, 30-387 Krakow, 13 Poland. 14 4 Department of Analytical Biochemistry, Faculty of Biochemistry, Biophysics and 15 Biotechnology, Jagiellonian University, Gronostajowa 7 St., 30-387, Krakow, Poland. 16 5 University of Gdansk, Faculty of Chemistry, Wita Stwosza 63, 80-308 Gdansk, Poland. 17 6 Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Medical 18 University of Silesia in Katowice, Silesian Centre for Heart Diseases, Zabrze, Poland. 19 7 Centre for Oral Health and Systemic Diseases, University of Louisville School of Dentistry, 20 Louisville, KY 40202, USA. 21 8 Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, 22 5020 Bergen, Norway 23 24 25 26 27 28 29 30 31 * Correspondence should be addressed to Krzysztof Pyrc ([email protected]), Virogenetics 32 Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian University, 33 Gronostajowa 7, 30-387 Krakow, Poland; Phone number: +48 12 664 61 21; www: 34 http://virogenetics.info/.
    [Show full text]
  • AACR2006-1686P
    Funding Proteinases and Inflammation Network Group grant Kallikrein 14 Signalling through Proteinase-Activated Receptors CIHR operating grant 1,2 3,4 3,4 3,4 5 Alberta Heritage Foundation for Katerina Oikonomopoulou , Kristina K. Hansen , Mahmoud Saifeddine , Illa Tea , Patricia Andrade-Gordon , Medical Research Graeme S. Cottrell6, Nigel W. Bunnett6, Nathalie Vergnolle3, Eleftherios P. Diamandis1,2 and Morley D. Hollenberg3,4 NSERC / CRSNG 1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto; 2Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto; 3Department of Pharmacology & Therapeutics, and 4Department of Medicine, University of Calgary, Calgary; 5Johnson & Johnson Pharmaceutical Research and Development, Spring House, Pennsylvania, 6Departments of Surgery and Physiology, University of California, San Francisco Kallikrein 14 can selectively disarm PAR (lower concentrations), OVERVIEW Figure 1: Mechanism of PAR activation (activation by proteolysis) 2. Kallikrein 14 can selectively disarm PAR1 (lower concentrations), 2+ Proteinase-activated receptors (PARs): a family of G-protein coupled receptors activated by serine proteinase cleavage site whilst activating PARs 2 and 4; Ca in HEK cells proteinases via a proteolytically revealed ‘tethered ligand’ (Fig. 1). Four family members (Fig. 2); PARs N PAR disarming 1, 2 and 4 signal to cells. N PAR1 dis-arming1 vs. activation Selective activation of PAR4 vs. PARs 1, 2 Human kallikreins (hKs): A 15-member family of secreted serine proteinases implicated in tumour 1 cm Thrombin 1 cm 2 min 2 min TFLLR-NH2 progression and cell survival (Fig. 4). (selective desensitization hK14: a tryptic kallikrein; wide tissue distribution, implicated in breast and ovarian cancer (Fig. 5 and 6). of PAR1) The mechanism of kallikrein action is not yet known: Although some targets have been identified (e.g.
    [Show full text]
  • Aberrant Human Tissue Kallikrein Levels in the Stratum Corneum and Serum of Patients with Psoriasis: Dependence on Phenotype, Severity and Therapy N
    CLINICAL AND LABORATORY INVESTIGATIONS DOI 10.1111/j.1365-2133.2006.07743.x Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy N. Komatsu,* à K. Saijoh,§ C. Kuk,* F. Shirasaki,à K. Takeharaà and E.P. Diamandis* *Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5G 1L5, Canada àDepartment of Dermatology and §Department of Hygiene, Graduate School of Medical Science, School of Medicine, Kanazawa University, Kanazawa, Japan Summary Correspondence Background Human tissue kallikreins (KLKs) are a family of 15 trypsin-like or Eleftherios P. Diamandis. chymotrypsin-like secreted serine proteases (KLK1–KLK15). Multiple KLKs have E-mail: [email protected] been quantitatively identified in normal stratum corneum (SC) and sweat as can- didate desquamation-related proteases. Accepted for publication 7 November 2006 Objectives To quantify KLK5, KLK6, KLK7, KLK8, KLK10, KLK11, KLK13 and KLK14 in the SC and serum of patients with psoriasis, and their variation Key words between lesional and nonlesional areas and with phenotype, therapy and severity. diagnostic marker, human kallikreins, psoriasis, The overall SC serine protease activities were also measured. serine proteases, stratum corneum, therapy Methods Enzyme-linked immunosorbent assays and enzymatic assays were used. Conflicts of interest Results The lesional SC of psoriasis generally contained significantly higher levels None declared. of all KLKs. KLK6, KLK10 and KLK13 levels were significantly elevated even in the nonlesional SC. The overall trypsin-like, plasmin-like and furin-like activities were significantly elevated in the lesional SC.
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • Download, Or Email Articles for Individual Use
    Florida State University Libraries Faculty Publications The Department of Biomedical Sciences 2010 Functional Intersection of the Kallikrein- Related Peptidases (KLKs) and Thrombostasis Axis Michael Blaber, Hyesook Yoon, Maria Juliano, Isobel Scarisbrick, and Sachiko Blaber Follow this and additional works at the FSU Digital Library. For more information, please contact [email protected] Article in press - uncorrected proof Biol. Chem., Vol. 391, pp. 311–320, April 2010 • Copyright ᮊ by Walter de Gruyter • Berlin • New York. DOI 10.1515/BC.2010.024 Review Functional intersection of the kallikrein-related peptidases (KLKs) and thrombostasis axis Michael Blaber1,*, Hyesook Yoon1, Maria A. locus (Gan et al., 2000; Harvey et al., 2000; Yousef et al., Juliano2, Isobel A. Scarisbrick3 and Sachiko I. 2000), as well as the adoption of a commonly accepted Blaber1 nomenclature (Lundwall et al., 2006), resolved these two fundamental issues. The vast body of work has associated 1 Department of Biomedical Sciences, Florida State several cancer pathologies with differential regulation or University, Tallahassee, FL 32306-4300, USA expression of individual members of the KLK family, and 2 Department of Biophysics, Escola Paulista de Medicina, has served to elevate the importance of the KLKs in serious Universidade Federal de Sao Paulo, Rua Tres de Maio 100, human disease and their diagnosis (Diamandis et al., 2000; 04044-20 Sao Paulo, Brazil Diamandis and Yousef, 2001; Yousef and Diamandis, 2001, 3 Program for Molecular Neuroscience and Departments of 2003;
    [Show full text]
  • Activation Profiles and Regulatory Cascades of the Human Kallikrein-Related Peptidases Hyesook Yoon
    Florida State University Libraries Electronic Theses, Treatises and Dissertations The Graduate School 2008 Activation Profiles and Regulatory Cascades of the Human Kallikrein-Related Peptidases Hyesook Yoon Follow this and additional works at the FSU Digital Library. For more information, please contact [email protected] FLORIDA STATE UNIVERSITY COLLEGE OF ARTS AND SCIENCES ACTIVATION PROFILES AND REGULATORY CASCADES OF THE HUMAN KALLIKREIN-RELATED PEPTIDASES By HYESOOK YOON A Dissertation submitted to the Department of Chemistry and Biochemistry in partial fulfillment of the requirements for the degree of Doctor of Philosophy Degree Awarded: Fall Semester, 2008 The members of the Committee approve the dissertation of Hyesook Yoon defended on July 10th, 2008. ________________________ Michael Blaber Professor Directing Dissertation ________________________ Hengli Tang Outside Committee Member ________________________ Brian Miller Committee Member ________________________ Oliver Steinbock Committee Member Approved: ____________________________________________________________ Joseph B. Schlenoff, Chair, Department of Chemistry and Biochemistry The Office of Graduate Studies has verified and approved the above named committee members. ii ACKNOWLEDGMENTS I would like to dedicate this dissertation to my parents for all your support, and my sister and brother. I would also like to give great thank my advisor, Dr. Blaber for his patience, guidance. Without him, I could never make this achievement. I would like to thank to all the members in Blaber lab. They are just like family to me and I deeply appreciate their kindness, consideration and supports. I specially like to thank to Mrs. Sachiko Blaber for her endless guidance and encouragement. I would like to thank Dr Jihun Lee, Margaret Seavy, Rani and Doris Terry for helpful discussions and supports.
    [Show full text]
  • A Multiparametric Serum Kallikrein Panel for Diagnosis of Non ^ Small
    Imaging, Diagnosis, Prognosis A Multiparametric Serum Kallikrein Panel for Diagnosis of Non ^ Small Cell Lung Carcinoma Chris Planque,1, 2 Lin Li,3 Yingye Zheng,3 Antoninus Soosaipillai,1, 2 Karen Reckamp,4 David Chia,5 Eleftherios P. Diamandis,1, 2 and Lee Goodglick5 Abstract Purpose: Human tissue kallikreins are a family of15 secreted serine proteases.We have previous- ly shown that the expression of several tissue kallikreins is significantly altered at the transcription- al level in lung cancer. Here, we examined the clinical value of 11members of the tissue kallikrein family as potential biomarkers for lung cancer diagnosis. Experimental Design: Serum specimens from 51 patients with non ^ small cell lung cancer (NSCLC) and from 50 healthy volunteers were collected. Samples were analyzed for11kallikreins (KLK1, KLK4-8, and KLK10-14) by specific ELISA. Data were statistically compared and receiver operating characteristic curves were constructed for each kallikrein and for various combinations. Results: Compared with sera from normal subjects, sera of patients with NSCLC had lower levels of KLK5, KLK7, KLK8, KLK10, and KLK12, and higher levels of KLK11, KLK13, and KLK14. Expres- sion of KLK11and KLK12 was positively correlated with stage.With the exception of KLK5, expres- sion of kallikreins was independent of smoking status and gender. KLK11, KLK12, KLK13, and KLK14 were associated with higher risk of NSCLC as determined by univariate analysis and con- firmed by multivariate analysis.The receiver operating characteristic curve of KLK4, KLK8, KLK10, KLK11,KLK12, KLK13, and KLK14 combined exhibited an area under the curve of 0.90 (95% con- fidence interval, 0.87-0.97).
    [Show full text]
  • Natural and Synthetic Inhibitors of Kallikrein-Related Peptidases (Klks)
    Biochimie 92 (2010) 1546e1567 Contents lists available at ScienceDirect Biochimie journal homepage: www.elsevier.com/locate/biochi Review Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs) Peter Goettig a,*, Viktor Magdolen b, Hans Brandstetter a a Division of Structural Biology, Department of Molecular Biology, University of Salzburg, Billrothstrasse 11, 5020 Salzburg, Austria b Klinische Forschergruppe der Frauenklinik, Klinikum rechts der Isar der TU München, Ismaninger Strasse 22, 81675 München, Germany article info abstract Article history: Including the true tissue kallikrein KLK1, kallikrein-related peptidases (KLKs) represent a family of fifteen Received 24 February 2010 mammalian serine proteases. While the physiological roles of several KLKs have been at least partially Accepted 29 June 2010 elucidated, their activation and regulation remain largely unclear. This obscurity may be related to the fact Available online 6 July 2010 that a given KLK fulfills many different tasks in diverse fetal and adult tissues, and consequently, the timescale of some of their physiological actions varies significantly. To date, a variety of endogenous þ Keywords: inhibitors that target distinct KLKs have been identified. Among them are the attenuating Zn2 ions, Tissue kallikrein fi active site-directed proteinaceous inhibitors, such as serpins and the Kazal-type inhibitors, or the huge, Speci city pockets fi Inhibitory compound unspeci c compartment forming a2-macroglobulin. Failure of these inhibitory systems can lead to certain Zinc pathophysiological conditions. One of the most prominent examples is the Netherton syndrome, which is Rule of five caused by dysfunctional domains of the Kazal-type inhibitor LEKTI-1 which fail to appropriately regulate KLKs in the skin.
    [Show full text]
  • Supplementary Figure 1. Scatterplots Showing the Assignment of Total RNA-Seq Reads and Measures of Human Genes and Bacterial Species Detected in Each Sample
    Supplementary Figure 1. Scatterplots showing the assignment of Total RNA-seq reads and measures of human genes and bacterial species detected in each sample. (A) Bacterial versus human-derived reads (millions). (B) Number of genes detected (minimum 20 assigned reads) versus human-derived reads (millions). (C) Number of bacterial species (minimum 20 assigned reads) versus bacterial-derived reads (millions). (D) Shannon diversity versus the number of bacterial-derived reads (millions). Supplementary Table 1. Patient #1 CT alignment CT gene CT protein SLIMM_all SLIMM_unique ompA Major Outer Membrane Protein 211 211 tmRNA noncoding RNA 173 173 omcA 9kDa-Cysteine-Rich Lipoprotein 100 100 omcB 60kDa Cysteine-Rich OMP 66 66 CT_398.1 noncoding RNA 61 61 groEL_1 HSP-60 39 39 ndk Nucleoside-2-P Kinase 33 33 CT_858 predicted Protease containing IRBP and DHR domains 29 29 tufA Elongation Factor Tu 28 28 hctB Histone-like Protein 2 24 24 yscC probable Yop proteins translocation protein C/general secretion pathway protein 23 23 CT_081 CHLTR T2 Protein 26 20 rpoC RNA Polymerase Beta' 24 20 CT_671 hypothetical protein 20 20 clpC ClpC Protease ATPase 19 19 CT_578 hypothetical protein 19 18 CT_664 adenylate cyclase-like protein 18 17 rho Transcription Termination Factor 15 15 glgA Glycogen Synthase 15 15 CT_456 hypothetical protein 14 14 CT_875 hypothetical protein 14 14 CT_708 SWF/SNF family helicase 13 13 dhnA Predicted 1%2C6-Fructose biphosphate aldolase (dehydrin family) 12 12 clpX CLP Protease ATPase 15 12 CT_082 hypothetical protein 13 11 nusA Transcription
    [Show full text]
  • Human KLK13 / Kallikrein-13 Protein (His Tag)
    Human KLK13 / Kallikrein-13 Protein (His Tag) Catalog Number: 10199-H08H General Information SDS-PAGE: Gene Name Synonym: KLK-L4; KLKL4 Protein Construction: A DNA sequence encoding the pro-form of human KLK13 (NP_056411.1) (Met 1-Ile 262) was expressed with a C-terminal polyhistidine tag. Source: Human Expression Host: HEK293 Cells QC Testing Purity: > 95 % as determined by SDS-PAGE Bio Activity： Protein Description Measured by its ability to cleave the fluorogenic peptide substrate Boc- VPR-AMC (R&D Systems, Catalog # ES011) . The specific activity is >200 Tissue kallikrein 13 (hK13), also known as KLK-L4 (kallikrein-like gene 4), pmoles/min/μg. (Activation description: The proenzyme needs to be is a member of the human tissue kallikrein family of serine proteases activated by Lysyl-Endopeptidase for an activated form) having diverse physiological functions in many tissues. The KLK13 gene resides on chromosome 19q13.3-4 along with other 14 members in a gene Endotoxin: cluster and shares a high degree of homology. KLK13 is a trypsin-like, secreted serine protease expressed specifically in the testicular tissue < 1.0 EU per μg of the protein as determined by the LAL method including prostate, salivary gland, breast, and testis. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and may Stability: play a role in metastasis. KLK13 may be involved in the pathogenesis Samples are stable for up to twelve months from date of receipt at -70 ℃ and/or progression of breast and ovary cancers, and is regarded as a novel cancer biomarker. In addition, KLK13 interacts and forms complexes with Predicted N terminal: Gly 18 several serum protease inhibitors, such as alpha2-macroglobulin, and its expression is regulated by steroid hormones.
    [Show full text]